3 Pharma stocks in which Axis group bought stake in Q3; Do you hold any?3 Pharma stocks in which Axis group bought stake in Q3; Do you hold any?

Introduction:

Axis Group is a prominent investment and financial services firm with a diverse portfolio. As per the latest corporate shareholdings filed, Axis Group publicly holds 112 stocks with a net worth of over ₹98,453.6 Cr., demonstrating strong market presence and strategic investments.

Apollo Hospitals Enterprise Ltd:

On February 7, 2025, Apollo Hospitals Enterprise Ltd opened at ₹6,921.45, down from its previous close of ₹6,874.25. The stock hit a high of ₹6,929.85 and a low of ₹6,750.00. By market close, it traded at ₹97,831.08, down 1.02%.

In Q3, Axis group acquired a 1.1% stake in Apollo Hospitals, a leading healthcare provider in India. The company is renowned for its extensive network of hospitals offering specialized medical services, diagnostics, and wellness programs across the country.

Apollo Hospitals Enterprise Ltd (NSE:APPOLLOHOSP) is one of India’s leading healthcare providers, offering a wide range of services, including hospitals, diagnostics, and pharmacies. It has a significant presence across the country and internationally, focusing on high-quality healthcare and innovative medical solutions.

Also Read: Solar energy stock jumps 4% after receiving order worth ₹967 Cr for solar pv projects

Cipla Ltd:

On February 7, 2025, Cipla Ltd opened at ₹1,473.50, slightly up from its previous close of ₹1,471.50. The stock hit a high of ₹1,481.85 and a low of ₹1,455.00. By market close, it traded at ₹1,470.00, down 0.10%, with a market cap of ₹1,18,719.26 crore.

Axis group bought a 1.2% stake in Cipla during Q3. Cipla is a major player in the pharmaceutical sector, focusing on manufacturing and distributing medicines for respiratory, oncology, and chronic diseases, making a significant impact on global healthcare markets.

Cipla Ltd (NSE:CIPLA) is a global pharmaceutical company known for manufacturing a broad portfolio of medicines across various therapeutic areas such as respiratory, oncology, and cardiovascular. The company is committed to improving the quality of life through affordable and accessible healthcare solutions.

Also Read: Fertilizer stock jumps 10% after its net profit increases by 183.5% YoY

Strides Pharma Science Ltd:

On February 7, 2025, Strides Pharma Science Ltd opened at ₹725.00, up from its previous close of ₹729.20. The stock hit a high of ₹759.90 and a low of ₹721.05. By market close, it traded at ₹745.95, up 2.30%, with a market cap of ₹6,874.88 crore.

In Q3, Axis group acquired a 1.5% stake in Strides Pharma. This pharmaceutical company is engaged in producing generic medicines and over-the-counter drugs, with a strong presence in emerging markets, providing affordable healthcare solutions and expanding its global reach.

Strides Pharma Science Ltd (NSE:STAR) is a pharmaceutical company specializing in the development, manufacturing, and distribution of generic medicines and over-the-counter drugs. It has a global presence and focuses on providing high-quality, affordable healthcare products to emerging markets.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.